reference/14099983

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/14099983

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase III\|Journal Article\|Multicenter Study\|Randomized Controlled Trial\|Research Support, Non-U.S. Gov't
endingPage	665
issn	1474-4422
issueIdentifier	7
pageRange	657-665
publicationName	The Lancet. Neurology
startingPage	657
bibliographicCitation	Calabresi PA, Kieseier BC, Arnold DL, Balcer LJ, Boyko A, Pelletier J, Liu S, Zhu Y, Seddighzadeh A, Hung S, Deykin A; ADVANCE Study Investigators. Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol. 2014 Jul;13(7):657–65. doi: 10.1016/s1474-4422(14)70068-7. PMID: 24794721.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_78aae1336f144eb4d8fd84624067de43 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_831cc7da0aaceffb971946c7a129162a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cfcc1c2b72e6912a52a21bc8a66039c8 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_89c4cde9d04112688ff4745614114f17 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e7b095e05b8d409395139baeabb01d20 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_017173f216dc23842fc8de48291d2c80 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5dcc46aad16c126b44cbb943208e4f55 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_56b03ab5ac662038852b10e87c4bb7a7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cd358c388f593bba98135803e28b034b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_520d59e1610bc457fa34c0de80102dcf http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_482ce380071c0e7cc99885eceb0c6ca0
date	201407
identifier	https://doi.org/10.1016/s1474-4422%2814%2970068-7 https://pubmed.ncbi.nlm.nih.gov/24794721
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/30413 https://portal.issn.org/resource/ISSN/1474-4422
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study
discusses	http://id.nlm.nih.gov/mesh/M0017182 http://id.nlm.nih.gov/mesh/M0025715 http://id.nlm.nih.gov/mesh/M0000431 http://id.nlm.nih.gov/mesh/M0230367
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D000276Q000627 http://id.nlm.nih.gov/mesh/D011092Q000627 http://id.nlm.nih.gov/mesh/D016899Q000627 http://id.nlm.nih.gov/mesh/D020529Q000175 http://id.nlm.nih.gov/mesh/D020529Q000188
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D016896 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D000068556 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D004311 http://id.nlm.nih.gov/mesh/D008875
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9556 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8532 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10606 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7732 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7907 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_7d6a1edc08997e3d7b61d7a07051efb5 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8911 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8174 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6642

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID3456 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID223365972

Total number of triples: 56.